Solid Biosciences

Solid Biosciences, founded in 2014, is a life science company with the slogan #TogetherWeAreSolid. The company is headquartered in Charlestown, MA, USA and operates within the Biotechnology and Health Care industries. Solid Biosciences focuses on advancing a portfolio of neuromuscular and cardiac programs for the treatment of diseases such as Duchenne, Friedreich’s ataxia, BAG3 mediated dilated cardiomyopathy, and additional cardiac diseases. Their mission is to serve as a center of excellence across the entire disease spectrum, bringing together expertise in science, technology, disease management, and care. With a clear mandate to attack the roots of diseases and improve daily life for patients, Solid Biosciences has secured a significant post-IPO equity investment of $109.00M from prominent investors including RA Capital Management, Invus, Adage Capital Management, Deerfield Management, Janus Handerson, Perceptive Advisors, Bain Capital Life Sciences, and Vestal Point Capital on 08 January 2024. The company's disease-focused approach, combined with its strong financial backing and diverse investor portfolio, positions Solid Biosciences as a key player in the advancement of treatments for neuromuscular and cardiac diseases.